<DOC>
	<DOCNO>NCT00916760</DOCNO>
	<brief_summary>The objective trial ass clinical efficacy modify extract ( depigmented polymerize glutaraldehyde ) subcutaneous injection Parietaria Judaica pollen treatment patient affect allergic rhinitis/rhinoconjunctivitis ( without episodic asthma ) induce hypersensitivity grass pollen , evaluate score regard symptom consumption medication .</brief_summary>
	<brief_title>Subcutaneous Immunotherapy Treatment Patients With Hypersensitivity Parietaria Judaica</brief_title>
	<detailed_description>Immunotherapy specific treatment allergic disease . Unlike conventional pharmacological treatment , immunotherapy treatment could modify natural course allergic disease . This prospective double-blind placebo control study two arm treatment : placebo active .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Informed consent , sign subject Positive clinical history rhinitis/rhinoconjunctivitis allergy Parietaria pollen Patient gender age 18 55 Diagnosed Sensitivity Parietaria pollen base : Positive Nasal provocation test Positive prick test P. Judaica Specific IgE P.Judaica &gt; 0,7KU/L Patients able comply dose regime Relevant sensitivity another perenne allergen Patient asthma Use immunotherapy last four year Treatment B . Blocking agent Patient suffer pathology adrenaline contraindicate Subject suffers serious medical condition , would interference treatment follow subject study Subject suffer autoimmune disease ( thyroiditis , lupus , etc . ) Conditions patient offer full cooperation nad significant psychiatric disturbance . Intolerance aspirin Pregnant woman pregnancy risk brestfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>allergic , rhinoconjunctivitis , Immunotherapy</keyword>
</DOC>